The colony-stimulating factors: use to prevent and treat neutropenia and its complications

Bibliography

• LYMAN GH, KUDERER NM: Economics of hematopoeitic growth factors.In: Hematopoietic Growth Factors in Oncology. Basic Science and Clinical Therapeutics. Morstyn G FM, Lieschke GJ (Eds), Humana Press, Inc., Totowa, NJ, USA (2004):409–443.
   Google Scholar
• METCALF D, FOSTER R: Bone marrow colony-stimulating activity of serum from mice with viral-induced leukaemia. Nati Cancer Inst. (1967) 39(6):1235–1245.
   PubMed Web of Science ®Google Scholar
• METCALF D: Studies on colony formationM vitro by mouse bone marrow cells. I. Continuous cluster formation and relationof clusters to colonies.Physiol. (1969) 74(3):323–332.
   Google Scholar
• CLARK S, KAMEN R: The human hematopoietic colony-stimulating factors. Science (1987) 236(4806):1229–1237.
   PubMed Web of Science ®Google Scholar
• BURGESS AW, CAMAKARIS J, METCALF D: Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. Biol. Chem. (1977) 252(6):1998–2003.
   Web of Science ®Google Scholar
• GOUGH NM, GOUGH J, METCALF D et al.: Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature (1984) 309(5971):763–767.
   PubMed Web of Science ®Google Scholar
• BURGESS AW, METCALF D: Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells. Int. Cancer (1980) 26(5):647–654.
   PubMed Web of Science ®Google Scholar
• MOORE MA: G-CSF: its relationship to leukaemia differentiation-inducing activity and other hemopoietic regulators.Physiol. Suppl. (1982) 1:53–64.
   Google Scholar
• WELTE K, PLATZER E, LU L et al.: Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc. Nati Acad. Sci. USA (1985) 82(5):1526–1530.
   PubMed Web of Science ®Google Scholar
• GABRILOVE JL, JAKUBOWSKI A, SCHER H et al.: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl.Med. (1988) 318(22):1414–1422.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, OZER H, STOLLER R et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl. Med. (1991) 325(3):164–170.
   PubMed Web of Science ®Google Scholar
• TRILLET-LENOIR V, GREEN J, MANEGOLD C et al.: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eui: Cancer (1993) 29A(3):319–324.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.Clin. Oncol. (1994) 12(11):2471–2508.
   Google Scholar
• NO AUTHORS LISTED: Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.Clin. Oncol. (1996) 14(6):1957–1960.
   PubMed Web of Science ®Google Scholar
• OZER H, ARMITAGE JO,BENNETT CL et al.: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.," Clin. Oncol. (2000) 18(20):3558–3585.
   Google Scholar
• ••Comprehensive evidence-based guidelinesand literature review for the use of CSFs. Further updated in 2004.
   Google Scholar
• MOORE MA: Colony stimulating factors: basic principles and preclinical studies. In: Principles and Practice of the Biologic Therapy of Cancer. Rosenberg SA (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2000):113–140.
   Google Scholar
• BAGBY GC, HEINRICH MC: Growth factors, cytokines, and the control of hematopoiesis. In: Hematology: Basic Principles and Practice. Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (Eds), Churchill Livingstone, Philadelphia, PA, USA (2000):154–202.
   Google Scholar
• PETROS W: Colony stimulating factors. In: Cancer Chemotherapy & Biotherapy Chabner BA, Longo DL (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001):829–850.
   Google Scholar
• ROSENFELD CS, SULECKI M, EVANS C, SHADDUCK RK: Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor inpatients with primary myelodysplasia.Exp. Hematol. (1991) 19(4):273–277.
   Google Scholar
• AMGEN: Neupogen (filgrastim). Package Insert (2002).
   Google Scholar
• BERLEX: Leuldne (sargramostim). Package Insert (2002).
   Google Scholar
• DORR RT: Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Gin. Thec (1993) 15(1):19–29; discussion 18.
   Google Scholar
• AMGEN: Neulasta (pegfilgrastim). Package Insert (2002).
   Google Scholar
• BIGANZOLI L, UNTCH M, SKACEL T, PICO JL: Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin. Oncol. (2004) 31(3 Suppl. 8):27–34.
   Google Scholar
• SWARTZBERG L: MASCC/ISOO 16th International Supportive Care in Cancer Symposium. Support. Care Cancer (2004) 12:361–376.
   Google Scholar
• LYMAN GH, KUDERER NM: The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit. Rev Oncol. Hematol. (2004) 50(2):129–146.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review for thecost-economic data of CSFs in prevention and treatment of FN.
   Google Scholar
• WADE JC: Management of infection in patients with acute leukaemia.Hematol. Oncol. Gin. North Am. (1993) 7(1):293–315.
   Google Scholar
• LYMAN GH, MORRISON VA, DALE DC et al.: Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leak. Lymphoma (2003) 44(12):2069–2076.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, DELGADO DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer (2003) 98(11):2402–2409.
   PubMed Web of Science ®Google Scholar
• •Retrospective survey of community oncology practices, including 1450 patients with NHL treated at 567 medical oncology practices. The study identifies timing and risk factors for FN.
   Google Scholar
• LYMAN GH, KUDERER NM, DJULBEGOVIC B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am. J. Med. (2002) 112(5):406–411.
   PubMed Web of Science ®Google Scholar
• ••A meta-analysis of 8 clinical trialsaddressing the role of CSFs with dose-intense chemotherapy.
   Google Scholar
• BENNETT CL, SMITH TJ, WEEKS JC et al.: Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin. Oncol (1996) 14(9):2511–2520.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, WEEKS JA, SOMERFIELD MR, FEINGLASS J, SMITH TJ: Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J. Clin. Oncol. (1999) 17(11):3676–3681.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, BALDUCCI L: A cost analysis of hematopoietic colony-stimulating factors. Oncology (Duntingt) (1995) 9(11 Suppl.):85–91.
   Google Scholar
• LYMAN GH, KUDERER N, GREENE J, BALDUCCI L: The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur. J Cancer (1998) 34(12):1857–1864.
   PubMed Web of Science ®Google Scholar
• DRUMMOND M, DAVIES L: Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer. Pharmacoeconomics (1994) 6\(Suppl. 2):44–52.
   Google Scholar
• MESSORI A, TRIPPOLI S, TENDI E: G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J.Pharm. Ther. (1996) 21(2):57–63.
   PubMed Web of Science ®Google Scholar
• SILBER JH, FRIDMAN M, SHPILSKY A et al: Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J. Clin. Oncol (1998) 16(7):2435–2444.
   PubMed Web of Science ®Google Scholar
• COSLER LE, CALHOUN EA, AGBOOLA O, LYMAN GH: Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy (2004) 24(4):488–494.
   PubMed Web of Science ®Google Scholar
• THATCHER N, GIRLING DJ, HOPWOOD P et al.: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.' Clin. Oncol (2000) 18(2):395–404.
   Web of Science ®Google Scholar
• LYMAN GH, LYMAN CG, SANDERSON RA, BALDUCCI L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Nati Cancer Inst. (1993) 85(6):488–493.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, KUDERER NM, CRAWFORD J, DALE D: Economic impact of pegfilgrastim use based on the risk of febrile neutropenia (FN) in NHL patients with CHOP. Proc. Am. Soc. Clin. Oncol (2003) 22:593.
   Google Scholar
• CLARK OA, LYMAN G, CASTRO AA, CLARK LG, DJULBEGOVIC B: Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst. Rev (2003) (3):CD003039.
   Google Scholar
• ••A Cochrane-based meta-analysis of 13 clinical studies assessing the utility of CSFs in FN.
   Google Scholar
• BERGHMANS T, PAESMANS M, LAFITTE JJ et al: Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support. Care Cancer (2002) 10(3):181–188.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis of CSFs in treating FN, including 8 clinical trials and 962 patients.
   Google Scholar
• CITRON ML, BERRY DA,CIRRINCIONE C et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukaemia Group B Trial 9741.j Oncol (2003) 21(8):1431–1439.
   Google Scholar
• •A randomised clinical study establishing the benefit of dose-dense chemotherapy in node-positive breast cancer patients.
   Google Scholar
• PFREUNDSCHUH M, TRUEMPER L, KLOESS M et al.: 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: resultsof the NHL-B2 trial of the DSHNHL. Blood (2004) 104(3):634–641.
   PubMed Web of Science ®Google Scholar
• PFREUNDSCHUH M, TRUEMPER L, KLOESS M et al.: 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood (2004) 104(3):626–633.
   PubMed Web of Science ®Google Scholar
• STEWARD WP, VON PAWEL J, GATZEMEIER U et al.: Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin. Oncol (1998) 16(2):642–650.
   PubMed Web of Science ®Google Scholar
• FONT A, MOYANO AJ, PUERTO JM et al.: Increasing dose intensity of cisplatin-etoposide in advanced non-small cell lung carcinoma: a Phase III randomized trial of the Spanish Lung Cancer Group. Cancer (1999) 85(4):855–863.
   PubMed Web of Science ®Google Scholar
• STERNBERG CN, DE MULDER PH, SCHORNAGEL JH et al: Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumours: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin. Oncol. (2001) 19(10):2638–2646.
   Google Scholar
• HEIL G, HOELZER D, SANZ MA et al:A randomized, double-blind, placebo-controlled, Phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukaemia. The International Acute Myeloid Leukaemia Study Group. Blood (1997) 90(12):4710–4718.
   Google Scholar
• ROWE JM, ANDERSEN JW, MAZZA JJ et al.: A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukaemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood(1995) 86(2):457–462.
   PubMed Web of Science ®Google Scholar
• DOMBRET H, CHASTANG C, FENAUX P et al.: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukaemia. AML Cooperative Study Group. N Engl. J. Med. (1995) 332(25):1678–1683.
   PubMed Web of Science ®Google Scholar
• STONE RM, BERG DT, GEORGE SL et al.: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. Cancer and Leukaemia Group B. N Engl. I Med. (1995) 332(25):1671–1677.
   PubMed Web of Science ®Google Scholar
• ZITTOUN R, SUCIU S, MANDELLI F et al.: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukaemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukaemia Cooperative Group.Chia. Omni (1996) 14(7):2150–2159.
   Google Scholar
• LOWENBERG B, BOOGAERTS MA, DAENEN SM et al: Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukaemia. Chia. Oncol (1997) 15(12):3496–3506.
   Google Scholar
• GODWIN JE, KOPECKY KJ, HEAD DR et al.: A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukaemia: a Southwest oncology group study (9031). Blood (1998) 91(103607–3615.
   Google Scholar
• BENNETT CL, STINSON TJ,TALLMAN MS et al.: Economic analysis of a randomized placebo-controlled Phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukaemia. Eastern Cooperative Oncology Group (E1490). Ann. anal (1999) 10(2):177–182.
   Google Scholar
• BENNETT CL, STINSON TJ,LAVER JH et al.: Cost analyses of adjunct colony stimulating factors for acute leukaemia: can they improve clinical decision making. Leak. Lymphoma (2000) 37(1–2):65–70.
   Google Scholar
• LOWENBERG B, VAN PUTTEN W, THEOBALD M et al.: Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukaemia. N Engl. Med. (2003) 349(8):743–752.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU JL, WITZ B, LIOURE B et al.: Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukaemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. Chia. Oncol (2000) 18(4):780–787.
   Google Scholar
• KOMROKJI R, BENNETT JM: The myelodysplastic syndromes: classification and prognosis. Carr: Hematol Rep. (2003) 2(3):179–185.
   PubMedGoogle Scholar
• GANSER A, HOELZER D: Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Semin. Hematol (1996) 33(3):186–195.
   PubMed Web of Science ®Google Scholar
• GREENBERG P, TAYLOR K,KOEFFLER P et al.: Phase III randomized multicenter trial of G-CSF versus observation for MDS. Blood (1993) 82\(Suppl. 1):196.
   Google Scholar
• HELLSTROM-LINDBERG E, AHLGREN T, BEGUIN Y et al.: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized Phase II study and long-term follow-up of 71 patients. Blood (1998) 92(1):68–75.
   PubMed Web of Science ®Google Scholar
• CASADEVALL N, DURIEUX P,DUBOIS S et al.: Health, economic, and quality of life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood (2004) 104(2):321–327.
   Google Scholar
• PUT CH, BOYETT JM, HUGHES WT et al: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukaemia. N Engl. I Med. (1997) 336(25):1781–1787.
   PubMed Web of Science ®Google Scholar
• LARSON RA, DODGE RK, LINKER CA et al: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukaemia: CALGB study 9111. Blood (1998) 92(5):1556–1564.
   PubMed Web of Science ®Google Scholar
• LAVER J, AMYLON M, DESAI S et al: Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T cell leukaemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. Chia. anal (1998) 16(2):522–526.
   Google Scholar
• KROGER N, ZANDER AR: Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leak. Lymphoma (2002) 43(7):1391–1394.
   PubMed Web of Science ®Google Scholar
• LEFRERE F, MAKKE J, FERMAND J et al: Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients withmultiple myeloma. Bone Marrow Transplant. (1999) 24(5):463–466.
   PubMed Web of Science ®Google Scholar
• D'HONDT L, EMMONS RV, ANDRE M et al.: The administration of 10 pg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. Leak. Lymphoma (1999) 34(1–2):105–109.
   Google Scholar
• KROGER N, ZELLER W, HASSAN HT et al.: Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann. Hematol (1998) 76(6):257–262.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, APPELBAUM F, SINGER J: Effect of GM-CSF on circulating granulocyte-monocyte progenitors in autologous bone marrow transplantation. Lancet (1989) 2(8676):1405–1406.
   PubMed Web of Science ®Google Scholar
• KLUMPP TR, MANGAN KF, GOLDBERG SL, PEARLMAN ES, MACDONALD JS: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial../. Chia. Omni (1995) 13(6):1323–1327.
   Google Scholar
• SPITZER G, ADKINS D, MATHEWS M et al.: Randomized comparison ofG-CSF + GM-CSF versus G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant. (1997) 20(11):921–930.
   PubMed Web of Science ®Google Scholar
• RINGDEN O, LABOPIN M,GORIN NC et al.: Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukaemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Chia. Omni (2004) 22(3):416–423.
   Google Scholar
• KOMROKJI RS, DIB EG, LIESVELD JL, PHILLIPS GL, LYMAN GH: Use of colony stimulating factors (G-CSF and GM-CSF) after allogeneic stem cell transplantation in adult patients: a meta-analysis of published studies. Proc. Am. Soc. Chia. Omni (2004) 23:590.
   Google Scholar
• HO VT, MIRZA NQ, JUNCO DD D, OKAMURA T, PRZEPIORKA D: The effect of hematopoietic growth factors on the risk of graft-versus-host disease after allogeneic hematopoietic stem cell 1909 transplantation: a meta-analysis. Bone Marrow Transplant. (2003) 32(8):771–775.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, KUDERER N,AGBOOLA O, BALDUCCI L: Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control (2003) 10(6):487–499.
   PubMedGoogle Scholar
• ••A comprehensive review of the utility ofCSFs in elderly patients.
   Google Scholar
• BALDUCCI L, HARDY CL,LYMAN GH: Hematopoietic growth factors in the older cancer patient.Curr. Opin. Hernatol (2001) 8(3):170–187.
   Google Scholar
• LYMAN GH, KUDERER NM: Cost effectiveness of myeloid growth factors in cancer chemotherapy. Can: Hernatol Rep. (2003) 2(6):471–479.
   Google Scholar
• LYMAN GH, DALE DC, CRAWFORD J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. Clin. Oncol (2003) 21(24):4524–4531.
   Web of Science ®Google Scholar
• LYMAN GH, DALE D, FRIEDBERG J, CRAWFORD J, FISHER RI: Incidence and predictors of low chemotherapy doseintensity in aggressive non-Hodgkin's lymphoma: a nationwide study. I. Clin. Oncol (2004) 22:4302–4311.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, BALDUCCI L, AGBOOLA Y: Use of hematopoietic growth factors in the older cancer patient. Oncol Spectra (2001) 2:414–421.
   Google Scholar
• DOORDUIJN JK, VAN DER HOLT B, VAN IMHOFF GW et al: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.Clin. Oncol (2003) 21(16):3041–3050.
   Google Scholar
• OSBY E, HAGBERG H, KVALOY S et al:CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood (2003) 101(10):3840–3848.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, KUDERER NM: Epidemiology of febrile neutropenia. Support. Cancer Ther. (2003) 1:23–25.
   PubMedGoogle Scholar
• SUNG L, NATHAN PC, LANGE B, BEYENE J, BUCHANAN GR: Prophylactic granulocyte colony-stimulating factor andgranulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J. Clin. Oncol (2004) 22(16):3350–3356.
   PubMed Web of Science ®Google Scholar